A Phase 1/2 Trial of VX15/2503 in Children Adolescents or Young Adults With Recurrent or Relapsed Solid Tumors

Study Overview

This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment.

Study Description

The purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of VX15/2503 administered as an intravenous infusion every 14 days to children with recurrent or refractory solid tumors; to define and describe the toxicities of VX15/2503 administered on this schedule; to characterize the pharmacokinetics of VX15/2503 in children with recurrent or refractory cancer; to preliminarily define the antitumor activity of VX15/2503 for the treatment of relapsed or refractory osteosarcoma; and to determine if VX15/2503 either improves the disease control rate at 4 months in patients with recurrent measurable osteosarcoma or produces an objective response rate in patients with relapsed or refractory osteosarcoma.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1802267915 (PHO-CROOP-COG-ADVL1614)
  • Research Study Identifier: TX8633
  • Principal Investigator: James Croop, MD, PhD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.